Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05595460 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 49 to confirmed 21 · Study sites: 15 to 13 · Primary completion date: Jun 2027 to Jul 2027 · 1 morev11 Show 4 more changesShow less
    • Enrollment target: estimated 49 to confirmed 21
    • Study sites: 15 to 13
    • Primary completion date: Jun 2027 to Jul 2027
    • Completion date: Mar 2029 to Jul 2027
  2. Re-verified, no change to tracked fieldsv10
  3. Enrollment target: 31 to 49 Study sites: 16 to 15 · Primary completion date: Mar 2027 to Jun 2027 · Eligibility criteria shortened, about 372 wordsv9 Show 3 more changesShow less
    • Study sites: 16 to 15
    • Primary completion date: Mar 2027 to Jun 2027
    • Eligibility criteria shortened, about 372 words

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Mar 1, 2025 to Mar 2027 Study sites: 11 to 16 · Completion date: Dec 2026 to Mar 2029v8 Show 2 more changesShow less
    • Study sites: 11 to 16
    • Completion date: Dec 2026 to Mar 2029
  5. Eligibility criteria shortened, about 294 words Secondary endpoints shortened, about 83 words · Study sites revised (11)v7 Show 2 more changesShow less
    • Secondary endpoints shortened, about 83 words
    • Study sites revised (11)

    See this version in full on ClinicalTrials.gov ↗

Show 5 earlier versionsHide 5 earlier versions
  1. Primary completion date: Apr 2024 to Mar 1, 2025 Study sites: 5 to 11v6 Show 1 more changeShow less
    • Study sites: 5 to 11
  2. Study sites: 4 to 5v5
  3. Study sites: 3 to 4v4
  4. Study sites: 1 to 3v3
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Oct 2022 to Oct 10, 2022v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Oct 2022 to Oct 10, 2022
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to determine the safety, preliminary antitumor activity, and pharmacokinetics (PK) of RYZ101 in combination with standard of care (SoC) therapy consisting of carboplatin + etoposide + atezolizumab in untreated subjects with somatostatin receptor expressing (SSTR+) ES-SCLC.
Trial Details
NCT Number NCT05595460
Lead Sponsor RayzeBio, Inc.
Conditions SCLC,Extensive Stage
Enrollment 21 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov